[ad_1]
The Latvian Institute of Organic Synthesis (LOSI) will launch a program of development of candidates for antiepileptics. After a successful implementation, the value of the project is estimated at around 30 million euros.
LOSI director Osvald Pugovich said that he was working on a memory booster, but that the treatment for epilepsy was positive and effective. . Initially, the Institute has held discussions with pharmaceutical companies, but they showed that the idea was not yet mature enough. Therefore, the Institute submitted a project to the Latvian Investment and Development Agency for the financing of the European Union Structural Funds in the technology transfer program, obtaining 300 EUR 000 for the development and marketing of the drug candidate. O. Pugovich predicts that, according to forecasts three years later, a chemical compound – a drug substance will be obtained. If a person buys the candidate substance, the first phase of the clinical trial will be monitored as to the safety of the new substance. If the safety measures are satisfactory, the effectiveness of the new product will be studied. According to O. Pugovich, preclinical data will be obtained over the next three years, the production technologies developed and their scale completed, and an additional four years will be required for clinical trials.
As director of LOSI, the Latvian Institute for Organic Synthesis independently and systematically explains the development of new drugs. has not been involved since the 80s of the last century, when a drug for cardiovascular disease was invented – Meldonium (Mildronate). Pugovich notes that one of the most promising directions for the development of the pharmaceutical industry could be the interest of major pharmaceutical companies in the field of medicine, including the anti-cancer drug preparation belinostat, created by the Institute in cooperation with other scientific institutions and commercial structures. to place research departments in Latvia. These young people studying science in Latvia will provide future career prospects. For example, O. Pugovich mentioned Lithuania, where historically there was a strong biotech industry with Soviet-era companies such as Sanitas and Fermentas, which were sold to Western companies but continue to grow. in Lithuania.
Source: LETA
- 07. 2018
[ad_2]
Source link
